S uperficial erosion of atherosclerotic plaques, a distinct pathway to coronary thrombosis of likely rising prevalence in the statin era, currently accounts for about one third of acute coronary syndromes. [1] [2] [3] Eroded plaques provoke thrombosis at focal areas of intimal endothelial cell (EC) loss without plaque fibrous cap rupture. 4 The composition of erosion-prone plaques differs markedly from that of ruptureprone plaques: those with erosion contain more proteoglycans, glycosaminoglycans, and smooth muscle cells but fewer macrophages and less lipid and necrotic cores than ruptured plaques. 5 Although the mechanisms that drive erosion remain poorly understood, the characteristic morphology and composition of eroded plaques suggest the operation of distinct pathophysiologic mechanisms.
plaques exhibit a higher content of NETs than plaques with rupture-prone or stable characteristics. 7 NETs can promote thrombosis directly by several mechanisms including acting as a solid-state reactor by entrapping circulating platelets and coagulation factors and activating platelets via neutrophil proteases and histones. [16] [17] [18] [19] [20] [21] Furthermore, NET-associated effectors including NE (neutrophil elastase), PR3 (proteinase 3), and histones as well as HOCl-produced locally by the abundant NET component MPO (myeloperoxidase)-can induce EC expression of TF (tissue factor), the initiator of the extrinsic coagulation cascade. [22] [23] [24] [25] These studies suggest that NETs may augment plaque thrombogenicity in several ways.
This study tested the hypothesis that NETs evoke activation and accentuate thrombogenicity of human vascular ECs. Our findings unveil a novel mechanism by which NETs can propagate and amplify endothelial dysfunction and induce thrombogenicity, in a process that depends on interleukin (IL)-1α and CatG (cathepsin G). The results provide new insight into the mechanisms of superficial erosion and have substantial translational potential given the availability of therapeutic antihuman IL-1α antibodies. 26 
Materials and Methods
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Reagents
GST (glutathione S-transferase)-pro-IL-1α and GST-pro-IL-1β fusion proteins purified from a wheat germ expression system were purchased from Abnova (Taipei, Taiwan), recombinant human IL-1α and IL-1β from Peprotech (Rocky Hill, NJ), thapsigargin from Abcam (Cambridge, MA), and fMLP (N-formyl-methionylleucyl-phenylalanine) from Sigma-Aldrich (St. Louis, MO). Anti-IL-1α-neutralizing antibody (MABp1) and IgG isotype control were obtained from Dr John Simard at XBiotech (Austin, TX) and anti-IL-1β-neutralizing antibody (canakinumab) from Dr Hermann Gram at Novartis (Basel, Switzerland). Anti-TF-neutralizing antibody (TF8-5G9) was provided by Drs James Morrisey and Kevin Croce. CatG from human neutrophils was purchased from Sigma-Aldrich, CatG inhibitor I from Cayman Chemical Co (Ann Arbor, MI), CatG substrate from Bachem (Torrance, CA), and NE substrate from EMD Millipore (Billerica, MA).
Cell Culture
Human saphenous vein ECs (HSVECs) or umbilical vein ECs (HUVECs) were harvested, respectively, from patients undergoing coronary artery bypass grafting or from umbilical cord segments as described. 27, 28 Human aortic ECs were purchased from Lonza Biologics (Portsmouth, NH). Cells were cultured on plates coated with 0.1% gelatin (Sigma-Aldrich) in Medium 199 (Lonza) supplemented with fetal bovine serum (FBS, 20% for HSVECs and human aortic ECs or 10% for HUVECs), penicillin-streptomycin, l-glutamine, heparin, and bovine hypothalamic EC growth supplement (Alfa Aesar, Haverhill, MA). After reaching confluence, HSVECs or human aortic ECs were incubated in OptiMEM (Lonza Biologics, Inc, Portsmouth, NH) supplemented with 3% FBS for 16 hours before the addition of the indicated reagents for various time periods as described in each experiment. Treatment of HUVECs with NETs was performed in HUVEC growth medium. Primary human monocytes were isolated by RosetteSep Human Monocyte Enrichment Cocktail (Stem Cell Technologies, Vancouver, Canada) following the manufacturer's instructions.
Preparation of NETs
Human neutrophils were isolated from buffy coats obtained from Massachusetts General Hospital. NETs were generated by stimulating neutrophils with 50 nmol/L phorbol myristate acetate for 4 hours, followed by extensive washing with PBS and NET isolation as described. 29 Some experiments used NETs prepared from neutrophils stimulated with 500 nmol/L thapsigargin for 4 hours. Characterization of NETs included DNA quantification using Sytox green nucleic acid labeling (Thermo Fisher Scientific, Inc, Waltham, MA); colorimetric assays that measured the enzymatic activity of NE+PR3 (0.142±0.022 U/ng DNA, n=7) and MPO (0.497±0.074 U/ ng DNA, n=6); fluorometric assays that determined the enzymatic activity of CatG (0.127±0.030 U/ng DNA, n=6); immunoblotting showing the presence of NE, PR3, CatG, and citrullinated histone H3 (R26) (H3Cit); and immunofluorescence microscopy that colocalized DNA with H3Cit and NE ( Figure I in the online-only Data Supplement).
RNA Isolation and Reverse TranscriptionQuantitative Polymerase Chain Reaction
Total RNA was isolated using an Ambion PureLink mini kit (Thermo Fisher Scientific, Inc) and reverse-transcribed by Superscript II (Invitrogen, Carlsbad, CA). Quantitative polymerase chain reaction was performed in a MyiQ Single-Color Real-Time polymerase chain reaction system using SYBR Green I (Bio-Rad, Hercules, CA). The mRNA levels of the genes tested were normalized to 18S or GAPDH as internal controls as indicated in each figure. The primer sequences were 18S, 5′- ATGGCCGTTCTTAGTTGGTG-3′  and 5′-GAACGCCACTTGTCCCTCTA-3′; GAPDH, 5′-GAAGG  TGAAGGTCGGAGTCA-3′ and 5′-AATGAAGGGGTCATTGATGG-3′;  VCAM-1 (vascular cell adhesion molecule 1), 5′-GTCAATGTTG  CCCCCAGAGA-3′ and 5′-TGCCTGCTCCACAGGATTTT-3′; ICAM-1  (intercellular adhesion molecule 1), 5′-AGCTTCGTGTCCTGTA  TGGC-3′ and 5′-TTT TCTGGCCACGTCCAGTT-3′; TF, 5′-GTCTT  CGCCCAGGTGGC-3′ and 5′-TGACTTAGTGCTTATTTGAACA  GTG-3′ .
Immunoblot and Cell Surface Biotinylation
Whole-cell lysates from 25,000 ECs were fractionated on 4% to 12% gradient SDS-PAGE gels (Life Technologies, Grand Island, NY) and transferred to polyvinylidene difluoride membranes. After blocking with 5% defatted milk and incubating with the appropriate Protease, TF, and MPO Activity Assays NE+PR3 activity was determined by incubating NETs with SuccinylAla-Ala-Pro-Val-p-nitroanilide in 50 mmol/L Tris-HCl buffer pH 7.5 at 37°C, quantifying the release of p-nitroaniline by measuring optical density (OD) at 410 nm every 2 minutes on a SpectraMax i3× multimode detection platform (Molecular Devices LLC, Sunnyvale, CA). CatG activity was determined by incubating NETs with Succinyl-Ala-Ala-Pro-Phe-7-amido-4-methyl-coumarin in 50 mmol/L Tris-HCl buffer pH 7.5 at 37°C, quantifying the release of 7-amino-4-methylcoumarin by measuring fluorescence (excitation, 370 nm; emission, 450 nm) every 2 minutes. MPO activity was assessed by incubating NETs with 3,3′,5,5′-tetramethylbenzidine, quantifying substrate oxidation by measuring OD at 650 nm every 2 minutes. One activity unit of NE or MPO is defined as the amount of activity corresponding to a ΔOD = 1 per hour under standard assay conditions. One activity unit of CatG is defined as the amount of activity corresponding to a ΔRFU = 1 per hour under standard assay conditions (RFU = relative fluorescence units).
To assess TF procoagulant activity, HSVECs were incubated with NETs for the time intervals indicated in each experiment and lysed by incubating with 15 mmol/L octyl-β-d-glucopyranoside (SigmaAldrich) at 37°C for 15 minutes. Activity was determined using a chromogenic assay (Abcam, Cambridge, UK) that measures levels of Factor X activation by the complex of cell lysate TF and exogenous Factor VII, following the manufacturer's instructions. One activity unit is defined as the activity corresponding to 1 pmol/L recombinant TF under the standard assay conditions.
Recalcification Clotting Assay
The effect of NETs on HSVEC's plasma clotting activity was assessed in 96-well plates by a modified recalcification assay previously described 32 using either intact monolayers or lysates from control or NET-treated HSVECs. One hundred microliters of cell lysates were incubated with 50 μL of pooled platelet-poor human plasma (George King Biomedical, Inc, Overland Park, KS) at 37°C for 2 minutes, followed by the addition of 50 μL of prewarmed 25 mmol/L CaCl 2 . The rate of fibrin formation was quantified by measuring OD at 405 nm every 10 seconds for 30 minutes. Clotting time is defined as the time elapsed between the first read and 50% of the maximal OD 405 reading. To assess clotting in the setting of an intact EC monolayer, HSVECs were stimulated with NETs for 8 hours, followed by 2 washes with Hanks' balanced salt solution and the addition of 150 μL of plasma. The clotting assay was then completed as described above.
Immunofluorescence
To visualize translocation of NFκB p65 to the nucleus, HSVECs were cultured on Permanox slides (Thermo Fisher Scientific, Inc) coated with Cultrex basement membrane extract (Trevigen, Gaithersburg, MD), treated with NETs for 90 minutes in OptiMEM containing 3% FBS and then fixed with 4% paraformaldehyde. Slides were stained overnight with 4'6-diamidino-2-phenylindole and with anti-NFκB p65 antibody (Abcam; catalog number: ab16502), followed by staining with goat antirabbit secondary antibody conjugated to Alexa Fluor 555 (Thermo Fisher Scientific, Inc). For NET staining, isolated NETs were fixed and stained as above with 4'6-diamidino-2-phenylindole and anti-H3cit or anti-NE (Abcam), followed by goat antirabbit secondary antibody conjugated to Alexa Fluor 555. Slides were visualized using a BX61WI microscope with an Olympus FV1000 confocal unit and photographed using an attached Olympus DP72 camera and Fluoview 10-ASW software.
Statistical Analysis
Results are presented as mean values±SEM. Data were analyzed to assess distribution normality. For normally distributed variables, statistical significance was assessed by Student unpaired t test (2 groups) or by ordinary 1-way ANOVA (>2 groups). For non-normally distributed variables, statistical significance was assessed by Mann-Whitney test (2 groups) or Kruskal-Wallis test for multiple comparisons (P<0.05 considered significant). Graphpad Prism software was used to run statistical tests.
Results

NETs Induce EC Expression of Leukocyte Adhesion Molecules
To test the hypothesis that NETs activate EC functions related to superficial erosion, this study evaluated the expression of VCAM-1 and ICAM-1 in HSVECs exposed to various concentrations of NETs for different time intervals. Compared with unstimulated controls, cells treated with NETs exhibited higher mRNA and protein concentrations corresponding to these adhesion molecules. The mRNA expression of VCAM-1 and ICAM-1, which depended on NET concentration, reached maximal levels at 3 to 6 hours of stimulation and then decayed ( Figure 1A and 1B) . The expression of VCAM-1 protein reached maximum at 6 to 12 hours, whereas the levels of ICAM-1 peaked at 12 hours and remained elevated up to 24 hours ( Figure 1C The experiments throughout this study used NETs produced by neutrophils stimulated with phorbol myristate acetate, a well-established method to elicit NETosis. 33, 34 NETs prepared in an independent manner from neutrophils stimulated with thapsigargin-a treatment that increases cytoplasmic Ca 2+ concentration and thus activates peptidylarginine deiminase 4 (PAD4), a Ca 2+ -dependent enzyme that causes DNA decondensation and NETosis-likewise induced expression of VCAM-1 and ICAM-1 in HSVECs ( Figure IV in the online-only Data Supplement). Conversely, the addition of medium conditioned by neutrophils treated with fMLP-a potent neutrophil activator that does not induce NETosis 34 -did not augment the expression of these adhesion molecules. were incubated with NETs (0.5 μg DNA/mL) for the indicated periods of time (left) or for 3 h with various concentrations of NETs (right), followed by RNA extraction and determination of VCAM-1 (vascular cell adhesion molecule 1) and ICAM-1 (intercellular adhesion molecule 1) mRNA levels by reverse transcription-quantitative polymerase chain reaction. Levels of GAPDH mRNA served as an internal control for adjustment between samples. Left, n=7; right, n=9. P values: *<0.05, **<0.01, ***<0.001, ****<0.0001 vs the respective controls. C, HSVECs were incubated with NETs (0.5 μg DNA/mL) for the indicated periods of time. Whole-cell extracts were fractionated by SDS-PAGE and immunoblotted with antibodies to VCAM-1, ICAM-1, or β-actin. D, Human umbilical cord endothelial cell (HUVECs) were treated with NETs (0.5 μg DNA/mL) for 6 h and analyzed by immunoblot as in (C). E, HUVECs were treated with NETs (0.5 μg DNA/mL) for 6 h, followed by analysis of the adhesion of THP-1 cells (left, n=4) or primary human monocytes (right, n=3) under flow as described in the Materials and Methods section.
IL-1α and CatG Mediate NET-Induced EC Activation
To explore the mechanism by which NETs activate ECs, we examined the content of various cytokines in NET preparations by ELISA. NETs contained IL-1α (2.1±1.1 pg/μg DNA; n=5) and IL-1β (2.4±1.4 pg/μg DNA; n=5). Human monoclonal antibodies to IL-1α (MABp1) or IL-1β (canakinumab), both used in clinical trials, 26, 35 enabled testing the effect of selective neutralization of IL-1 isoforms on NET-induced expression of VCAM-1 and ICAM-1 in ECs. Assessing the effect of these antibodies on VCAM-1 expression in HSVECs stimulated with recombinant IL-1α or IL-1β validated their specificity. Anti-IL-1α abrogated VCAM-1 expression induced by IL-1α but not by IL-1β, whereas anti-IL-1β inhibited VCAM-1 expression elicited by IL-1β but not by IL-1α. IL-1Ra (interleukin-1 receptor antagonist), which blocks the IL-1 receptor 1 that mediates the effect of both IL-1 isoforms, inhibited VCAM-1 expression induced by either IL-1α or IL-1β as expected (Figure 2A Figure 2F ) and by translocation of NFκB p65 to the nucleus of HSVECs ( Figure 2G) .
NETs contain an array of molecules that participate in neutrophils' host defense functions. This arsenal includes the serine proteases NE, PR3, and CatG, enzymes implicated in the pathogenesis of several human diseases. [36] [37] [38] Further experiments investigated whether these proteases participate in the induction of adhesion molecules elicited by NETs in ECs. HSVEC stimulation experiments included 3% FBS, a condition that suppressed the activity of NE and PR3 present in NETs as assessed by determination of the rate of hydrolysis of Succinyl-Ala-Ala-Pro-Val-p-NA, a common substrate for both proteases. This inhibition likely reflects the action of blood antiproteinases. In contrast, NETs retained 30% to 40% of their CatG activity in the presence of 3% FBS, evaluated by measuring the hydrolysis of Succinyl-Ala-AlaPro-Phe-MCA. Indeed, either fetal bovine or human sera inhibited the activity of these serine proteases differentially ( Figure Proteolytic processing enhances the biological activity of the IL-1α precursor, but unprocessed pro-IL-1α can still bind to the IL-1 receptor and activate target cells. 39, 40 Conversely, IL-1β requires proteolytic processing of its precursor to attain biological activity. The observation that IL-1α but not IL-1β mediates NET-induced EC activation prompted the examination of the effect of NETs on IL-1 isoforms in vitro. Incubation of NETs with recombinant pro-IL-1α fused to the C terminus of GST resulted in cleavage of the precursor yielding 16 to 18 kDa polypeptides corresponding in molecular weight to mature IL-1α ( Figure 3A , left). The addition of 3% FBS, a condition that inhibits elastase and PR3, but not CatG, resulted in the elaboration of only the faster-migrating polypeptide, which has a mobility identical to the polypeptide generated by incubation of GST-pro-IL-1α with recombinant CatG (Figure 3A Treatment of HSVECs with pro-IL-1α or with cleaved IL-1α induced the expression of VCAM-1 and ICAM-1 ( Figure 3C ). The addition of CatG and DNA in similar quantities to those found in NETs increased the effect of pro-IL-1α but not of cleaved IL-1α, indicating that the effect of CatG stems primarily from its ability to process the IL-1α precursor and yield a more active cytokine. CatG-added together with DNA ( Figure 3C Figure 3C) . Collectively, the results indicate that NETs induce EC activation in a process that depends on IL-1α and that involves processing of the IL-1α precursor by CatG.
NETs Augment HSVEC Thrombogenicity Through Induction of TF Expression
Evaluation of the effect of NETs on EC thrombogenicity involved exposure of HSVECs to NETs at various Levels of GAPDH mRNA served as an internal control for adjustment between samples. B, HSVECs were incubated with NETs (0.5 μg DNA/mL) for the indicated periods of time (left, n=8) or for 6 h with various concentrations of NETs (right, n=6), followed by cell lysis and determination of TF activity as described in the Materials and Methods section. C, HSVECs were incubated with NETs (0.5 μg DNA/mL) for 3 h in the presence of the indicated antibodies (20 ng/mL), IL-1Ra (interleukin-1 receptor antagonist; 1 μg/mL), or CatG (cathepsin G) inhibitor I (50 μmol/L), followed by RNA extraction and determination of TF mRNA levels by RT-qPCR. n=4 to 9. P values: *<0.05, **<0.01, ***<0.001, ****<0.0001 vs the respective controls (A-D) or vs NETs alone, defined as 100% (E).
concentrations and times and examination of the expression and activity of TF. NETs increased TF mRNA expression with a peak after 3 hours ( Figure 4A, left) , accompanied by augmented TF activity that peaked at 6 hours and remained elevated after 24 hours of treatment ( Figure 4B, left) . These effects depended on NET concentration ( Figure 4A Figure 5C ) and abrogated NET-stimulated acceleration of plasma clotting by HSVEC lysates ( Figure 5D ). Cell treatment with NETs did not significantly change mRNA expression of other proteins involved in blood coagulation such as TF pathway inhibitor, thrombomodulin, or Von Willebrand factor (not shown).
Together, these data demonstrate that increased TF production after exposure of HSVECs to NETs augments their thrombogenicity.
Discussion
Superficial erosion of human coronary arterial plaques often causes thrombosis and acute coronary syndromes. Yet no contemporary therapies target superficial erosion specifically, in part because the mechanisms that underlie this condition remain poorly understood. Endothelial dysfunction seems to participate critically in the pathophysiology of superficial erosion. Activated ECs promote neutrophil recruitment to plaques and release of NETs, which localize to the surface of human plaques with morphological characteristics associated with superficial erosion. 2, 6, 7, 41 This study demonstrated that NETs can amplify and propagate local processes that lead to endothelial injury by eliciting EC activation and increased adhesivity, which in turn could promote further leukocyte recruitment to lesion sites and thus potentiate the regional inflammatory response. Additionally, NETs induced TF expression and accelerated plasma clotting by ECs. Collectively, these results illustrate a novel mechanism by which NETs can aggravate thrombosis at sites of superficial erosion of atherosclerotic plaques ( Figure 6 ). NETs are multimolecular structures composed of chromatin decorated with granular and cytoplasmic proteins released by neutrophils undergoing a specialized form of cell death. 14, 42 Examination of the content and function of various cytokines present in NETs revealed that these structures contain both IL-1 isoforms. Two decades before the discovery of NETs, Tiku et al 43 reported that neutrophils stimulated with soluble (phorbol myristate acetate) or insoluble (zymosan) agonists released IL-1, a cytokine not expressed by resting neutrophils. Subsequent studies demonstrated IL-1 expression by isolated neutrophils treated with various proinflammatory stimuli and in those in the synovial fluid of patients with rheumatoid arthritis. [44] [45] [46] Association with NETs should retain IL-1 isoforms and other potent effector molecules at sites of intimal injury and furnish a solid-state scaffold for their concerted actions to amplify and propagate the local response.
The present study demonstrated that IL-1α, but not IL-1β, mediates the action of NETs on the aspects of EC activation examined here. This finding was somewhat surprising given that both IL-1 isoforms share a common cell surface receptor, elicit the same signaling pathways, and exhibit considerable redundancy in their action on target cells. 47, 48 The observation, however, agrees with the known role of IL-1α as a danger signal when released by dead and dying cells, where it initiates inflammatory responses characterized by neutrophil recruitment to injury sites. 49, 50 IL-1α and IL-1β have distinct biochemical, cell biological, functional, and pathophysiologic aspects, 40, 48 including exhibiting different requirements for proteolytic processing to exert biological activity. IL-1α possesses activity without processing, but cleavage of its precursor with generation of a 16 to 18 kDa C-terminal fragment can enhance its activity. IL-1β, in contrast, requires proteolytic processing to attain biological activity through highly regulated intracellular pathways that involve the inflammasomes and multiple triggering stimuli and costimuli that result in caspase-1 activation. 39, 40, 48 IL-1 isoforms can also undergo proteolytic processing extracellularly after being released by damaged or dying cells. We previously reported differential processing of IL-1β by various matrix metalloproteinases implicated in atherogenesis.
51 Figure 6 . Interleukin (IL)-1α mediates endothelial cell activation by neutrophil extracellular traps. When neutrophils undergo NETosis, the extruded DNA strands associate with numerous proteins including the precursor forms of IL-1α and β and serine proteinases produced by the granulocytes. The results presented here show that the neutrophil-derived proteinase cathepsin G processes pro-IL-1α to the more active mature form by limited proteolysis but degrades pro-IL-1β to inactive fragments. This pathway likely operates in vivo, as cathepsin G retains activity even in the presence of plasma proteinase inhibitors. Neutrophil extracellular traps (NETs) bearing mature IL-1α can activate endothelial cells to express adhesion molecules that can recruit further leukocytes and elicit the local production of the potent procoagulant tissue factor. Thus, activation of endothelial cells by this NET-associated cytokine can amplify, sustain, and propagate local vascular inflammation and also promote thrombosis. These results have particular importance for postulated mechanisms of thrombosis because of superficial erosion. We have proposed a multi-hit pathway for the pathogenesis of this mode of arterial thrombosis: an initial endothelial desquamation with inadequate local repair, followed by an amplification phase. NET-associated IL-1α could participate in the amplification phase by aggravating the consequences of local endothelial erosion and promotion of the formation and persistence of arterial thrombi that lead to clinical events.
Although several purified proteases can process either IL-1 isoform yielding the corresponding mature, more active polypeptides, 39, 40, [52] [53] [54] [55] [56] [57] the present data indicate that NETs exert differential effects on IL-1 isoforms, processing the IL-1α precursor to a more active form via limited proteolysis but degrading the IL-1β precursor more completely. These results explain the present study's finding that IL-1α, but not IL-1β, mediates the effects of NETs on ECs and suggest that the lack of redundancy of IL-1 in various pathophysiologic scenarios may stem in part from their differential susceptibility to proteolysis. CatG seems to be the most relevant NET-associated protease participating in pro-IL-1α processing under the experimental conditions of this study. Incubation of pro-IL-1α with NETs yields a product of identical electrophoretic mobility to that generated by purified CatG. Moreover, unlike NE or PR3, CatG retains enzymatic activity in the presence of endogenous proteinase inhibitors in blood. Also, a recent study showed that NE associated with NETs exhibits low activity. 58 Our results demonstrate a novel pathway by which local IL-1α processing by NET-associated CatG at the intimal surface acts analogously to activation of pro-IL-1β by caspase-1 in inflammasomes in other circumstances.
The work reported here documents that NETs can induce the EC expression of TF-a critical modulator of the thrombogenicity of human atheromata- 59 which results in the acceleration of plasma clotting by EC lysates or monolayers. NETs did not exhibit detectable TF activity in cell-free assays in the present study, while NETs isolated from the blood withdrawn from culprit arteries of patients with acute coronary syndrome contain TF. 60 This result, which concurs with a recent report by Noubouossie et al, 61 suggests that neutrophils do not act as the primary source of TF found in NETs detected in acute coronary syndrome (ACS) patients. Rather, in addition to their prothrombotic action on ECs, NETs may aggravate thrombosis by providing a surface that can bind TF released from dying cells or circulating in the blood, as well as trapping platelets, further leukocytes, and fibrin.
Data from our recent study that categorized human atherosclerotic plaques based on morphological features revealed an association of neutrophils and NETs with eroded plaques but not with rupture-prone plaques. 7 The present work supports a growing body of evidence indicating that NETs contribute pivotally to coronary thrombosis in the setting of superficial erosion and may, therefore, comprise therapeutic targets. Other recent data from our group affirms this concept by demonstrating that NETs participate causally in acute thrombotic complications of intimal lesions tailored in mice to recapitulate features of superficial erosion in humans. 8 This experimental approach demonstrated that abrogation of NETosis by genetic deficiency of peptidyl arginine deiminase 4 or promoting disassembly of NETs by administration of soluble DNAse I reduced intimal permeability, endothelial injury and death, endothelial expression of TF, and thrombosis.
Imaging of culprit lesions with intravascular optical coherence tomography can now differentiate erosion from rupture in patients with ACS. Patients with ruptured or intact fibrous caps present distinct expression profiles of intracoronary cytokines. 62 This differential cytokine expression can help understand the mechanisms underlying ACS but may not suffice as a diagnostic tool to discriminate between plaque erosion and rupture. Blood biomarkers of NETosis such as free DNA or citrullinated histones might provide a means to distinguish erosion from rupture noninvasively at point of care on presentation. Such advances might guide more precision treatment of ACS based on pathobiologic mechanisms rather than the surface ECG, 63 as erosion may respond best to management strategies distinct from those appropriate for rupture. 10, 64 The availability of selective anti-IL-1α antibodies already in use in clinical investigation points to the ready translatability of the results presented here. Administration of such agents acutely to patients with ACS caused by superficial erosion might mitigate the amplification and propagation of local thrombosis. Moreover, because reperfusion injury or no-reflow may involve EC interaction with neutrophils and possibly NETosis, anti-IL-1α therapy merits consideration as adjunctive therapy in these conditions as well. The recent demonstration that long-term administration of an anti-IL-1β antibody can reduce recurrent cardiovascular events in patients in the stable phase post ACS who have persistent inflammation validates the feasibility and concept of targeting of IL-1 therapeutically with a monoclonal antibody in coronary artery disease. 35 The present data provide a mechanistic basis for a strategy of short term acute treatment of patients with ACS due to erosion with an anti-IL-1α inhibitor. Such an acute intervention could precede a more prolonged chronic treatment with an anti-IL-1β inhibitor or broader spectrum anti-inflammatory therapy in those with residual inflammatory risk, given the evidence for distinct drivers of inflammation in the acute and chronic phases of atherothrombosis.
